385 related articles for article (PubMed ID: 31490007)
21. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
23.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
24. Genotype-phenotype associations among panel-based TP53+ subjects.
Rana HQ; Clifford J; Hoang L; LaDuca H; Black MH; Li S; McGoldrick K; Speare V; Dolinsky JS; Gau CL; Garber JE
Genet Med; 2019 Nov; 21(11):2478-2484. PubMed ID: 31105275
[TBL] [Abstract][Full Text] [Related]
25. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne.
Kast K; Rhiem K; Larsen M; Wappenschmidt B; Schmutzler R
Cancer Med; 2024 Feb; 13(3):e6920. PubMed ID: 38230850
[TBL] [Abstract][Full Text] [Related]
26. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel.
Coffee B; Cox HC; Kidd J; Sizemore S; Brown K; Manley S; Mancini-DiNardo D
Cancer Genet; 2017 Feb; 211():5-8. PubMed ID: 28279308
[TBL] [Abstract][Full Text] [Related]
27. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients.
Yamaguchi K; Urakami K; Nagashima T; Shimoda Y; Ohnami S; Ohnami S; Ohshima K; Mochizuki T; Hatakeyama K; Serizawa M; Akiyama Y; Maruyama K; Katagiri H; Ishida Y; Takahashi K; Nishimura S; Terashima M; Kawamura T; Kinugasa Y; Yamakawa Y; Onitsuka T; Ohde Y; Sugino T; Ito I; Matsubayashi H; Horiuchi Y; Mizuguchi M; Yamazaki M; Inoue K; Wakamatsu K; Sugiyama M; Uesaka K; Kusuhara M
Biomed Res; 2016; 37(4):259-64. PubMed ID: 27545002
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
32. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
[TBL] [Abstract][Full Text] [Related]
33.
Ea V; Berthozat C; Dreyfus H; Legrand C; Rousselet E; Peysselon M; Baudet L; Martinez G; Coutton C; Bidart M
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892462
[TBL] [Abstract][Full Text] [Related]
34. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
35. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
[TBL] [Abstract][Full Text] [Related]
36. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
37. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
Kwong A; Shin VY; Ho CYS; Au CH; Slavin TP; Weitzel JN; Chan TL; Ma ESK
BMC Cancer; 2020 Nov; 20(1):1053. PubMed ID: 33138793
[TBL] [Abstract][Full Text] [Related]
38. TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge.
Grill S; Ramser J; Hellebrand H; Pfarr N; Boxberg M; Brambs C; Ditsch N; Meindl A; Groß E; Meitinger T; Kiechle M; Quante AS
Arch Gynecol Obstet; 2021 Jun; 303(6):1557-1567. PubMed ID: 33245408
[TBL] [Abstract][Full Text] [Related]
39. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
40. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
